PYY-Dependent Restoration of Impaired Insulin and Glucagon Secretion in Type 2 Diabetes following Roux-En-Y Gastric Bypass Surgery
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Roux-en-Y gastric bypass (RYGB) is a weight-reduction procedure resulting in rapid resolution of type 2 diabetes (T2D). The role of pancreatic islet function in this restoration of normoglycemia has not been fully elucidated. Using the diabetic Goto-Kakizaki (GK) rat model, we demonstrate that RYGB restores normal glucose regulation of glucagon and insulin secretion and normalizes islet morphology. Culture of isolated islets with serum from RYGB animals mimicked these effects, implicating a humoral factor. These latter effects were reversed following neutralization of the gut hormone peptide tyrosine tyrosine (PYY) but persisted in the presence of a glucagon-like peptide-1 (GLP-1) receptor antagonist. The effects of RYGB on secretion were replicated by chronic exposure of diabetic rat islets to PYY in vitro. These findings indicate that the mechanism underlying T2D remission may be mediated by PYY and suggest that drugs promoting PYY release or action may restore pancreatic islet function in T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bariatric Surgery: A Systematic Review and Meta-analysis
Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M. D., Pories, W., Fahrbach, K., & Schoelles, K. (2004) · JAMA · doi:10.1001/jama.292.14.1724 · Cited by 6,800
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604 · cited 1×
“Circulating PYY levels are drastically reduced in obesity and T2D (Batterham et al., 2003).”
BackgroundTremaroli, V., Karlsson, F., Werling, M., Ståhlman, M., Kovatcheva-Datchary, P., Olbers, T., Fändriks, L., le Roux, C. W., Nielsen, J., & Bäckhed, F. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.07.009 · Cited by 757
Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
Unger, R. H., & Cherrington, A. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60016 · Cited by 670
Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells
Chimerel, C., Emery, E., Summers, D. K., Keyser, U., Gribble, F. M., & Reimann, F. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.032 · Cited by 548 · cited 2×
“These findings indicate that the mechanism underlying T2D remission may be mediated by PYY and suggest that drugs promoting PYY release or action may restore pancreatic islet function in T2D.”
BackgroundSalehi, M., Prigeon, R. L., & D’Alessio, D. A. (2011) · Diabetes · doi:10.2337/db11-0203 · Cited by 323 · cited 2×
“…University of Science and Technology, 7491 Trondheim, Norway 3Metabolic Research, Department of Physiology, Institute of Neuroscience and Physiology, University of Goteborg, Box 432, 40530 Göteborg, Sweden *Correspondence:…”
BackgroundZhang, Q., Ramracheya, R., Lahmann, C., Tarasov, A., Bengtsson, M., Braha, O., Braun, M., Brereton, M., Collins, S., Galvanovskis, J., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.10.014 · Cited by 225
Self-citationRamracheya, R., Ward, C., Shigeto, M., Walker, J. N., Amisten, S., Zhang, Q., Johnson, P. R., Rorsman, P., & Braun, M. (2010) · Diabetes · doi:10.2337/db09-1505 · Cited by 136 · cited 2×
“Insulin measurements were performed at 20 mM glucose, but in some cases, to maximize glucagon inhibition from the same islets, stimulated secretion was performed at 6 mM glucose (Ramracheya et al., 2010).”
MethodSelf-citation
Research works printed but not linked: 20
- Adrian, 1985, Human distribution and release of a putative new gut hormone, peptide YY, Gastroenterology, 89, 1070, 10.1016/0016-5085(85)90211-2 · DOI · Paper page
- Cerf, 2006, Transcription factors regulating beta-cell function, Eur. J. Endocrinol., 155, 671, 10.1530/eje.1.02277 · DOI
- Chan, 2006, Peptide YY levels are elevated after gastric bypass surgery, Obesity (Silver Spring), 14, 194, 10.1038/oby.2006.25 · DOI
- Chandarana, 2013, Peripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance, Mol. Metab., 2, 142, 10.1016/j.molmet.2013.03.001 · DOI · Paper page
- Clements, 2004, Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus, Am. Surg., 70, 1, 10.1177/000313480407000101 · DOI · Paper page
- Höög, 1997, Ultrastructural localization of insulin-like growth factor-2 (IGF-2) to the secretory granules of insulin cells: a study in normal and diabetic (GK) rats, Ultrastruct. Pathol., 21, 457, 10.3109/01913129709021946 · DOI
- Jørgensen, 2013, Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes, Diabetes, 62, 3044, 10.2337/db13-0022 · DOI · Paper page
- Kodama, 2013, Mechanistic comparison between gastric bypass vs. duodenal switch with sleeve gastrectomy in rat models, PLoS ONE, 8, e72896, 10.1371/journal.pone.0072896 · DOI
- Lake, 1989, Large-scale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell separator, Diabetes, 38, 143, 10.2337/diab.38.1.S143 · DOI · Paper page
- Lee, 2012, Metabolic manifestations of insulin deficiency do not occur without glucagon action, Proc. Natl. Acad. Sci. USA, 109, 14972, 10.1073/pnas.1205983109 · DOI · Paper page
- Lindqvist, 2013, Effects of ingestion routes on hormonal and metabolic profiles in gastric-bypassed humans, J. Clin. Endocrinol. Metab., 98, E856, 10.1210/jc.2012-3996 · DOI
- Marchetti, 2012, A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets, Diabetologia, 55, 3262, 10.1007/s00125-012-2716-9 · DOI · Paper page
- Mokadem, 2014, Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency, Mol. Metab., 3, 191, 10.1016/j.molmet.2013.11.010 · DOI · Paper page
- Persaud, 2014, Peptide YY: more than just an appetite regulator, Diabetologia, 57, 1762, 10.1007/s00125-014-3292-y · DOI
- Pittner, 2004, Effects of PYY[3-36] in rodent models of diabetes and obesity, Int. J. Obes. Relat. Metab. Disord., 28, 963, 10.1038/sj.ijo.0802696 · DOI · Paper page
- Pournaras, 2010, Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes, Ann. Surg., 252, 966, 10.1097/SLA.0b013e3181efc49a · DOI · Paper page
- Sam, 2012, Selective ablation of peptide YY cells in adult mice reveals their role in beta cell survival, Gastroenterology, 143, 459, 10.1053/j.gastro.2012.04.047 · DOI
- Shin, 2010, Meal-induced hormone responses in a rat model of Roux-en-Y gastric bypass surgery, Endocrinology, 151, 1588, 10.1210/en.2009-1332 · DOI · Paper page
- Tan, 2014, Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose, J. Clin. Endocrinol. Metab., 99, E2317, 10.1210/jc.2014-2143 · DOI
- Ye, 2014, GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents, Am. J. Physiol. Regul. Integr. Comp. Physiol., 306, R352, 10.1152/ajpregu.00491.2013 · DOI · Paper page
Cited by
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 289
Incretin hormones and type 2 diabetes
Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153
Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetes
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2021) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000612 · Cited by 42
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Metadata
- Authors
- Ramracheya, R. D., McCulloch, L. J., Clark, A., Wiggins, D., Johannessen, H., Olsen, M. K., Cai, X., Zhao, C.-M., Chen, D., & Rorsman, P.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 15
- Issue
- 5
- Pages
- 944-950
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2338614470
- Cited by
- 92
- References
- 8
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.